Bavarian Nordic says first milestone payment under new J & J deal could be in 2019
COPENHAGEN (Reuters) - Danish biotech company Bavarian Nordic expects to get a first milestone payment under a new deal with Janssen Pharmaceuticals in 2019, if clinical trials for vaccines targeting hepatitis B and HIV-1 get underway next year, a company executive said.
Source: Reuters: Health - Category: Consumer Health News Tags: healthNews Source Type: news
More News: Biotechnology | Clinical Trials | Denmark Health | Health | Hepatitis | Hepatitis B | Hepatitis Vaccine | Vaccines